Skip to main
GRDN

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Services Inc. is poised for a positive financial outlook due to its differentiated pharmacy services, leveraging strong technology capabilities to enhance value-based care and operational efficiency. The company boasts significant market share and attractive earnings potential, particularly from its recently acquired facilities, supported by a robust tech stack and advanced robotic dispensing that improves accuracy and speeds up fulfillment times to under one day. Collectively, these factors underscore Guardian’s ability to drive better clinical outcomes and reduce care costs for residents in long-term care facilities, enhancing its overall growth prospects.

Bears say

The financial outlook for Guardian Pharmacy Services Inc is negatively impacted by several key risks, notably potential regulatory and reimbursement changes that could affect revenue streams. Additionally, challenges in relationship management within long-term care facilities (LTCFs) and supply chain disruptions pose significant hurdles to operational stability. Furthermore, the company's reliance on technology assets and difficulties in hiring and retaining clinical staff may hinder its ability to maintain service quality and effectively integrate acquisitions, all contributing to a cautious financial perspective.

GRDN has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 3 analysts, GRDN has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.